6-K ·Filed Apr 22, 2026
Notable filing: 6-K
Actionable Insight • Neutral
Monitor for future updates on the commercial strategy for givastomig and VIS-101, as Hagler's appointment signals a focus on maximizing pipeline value and preparing for potential market entry.
Final — all horizons settled through T+60d
NBP ▼ -31.01% at T+60d
NEUTRAL call -31.01% · α vs SPY -35.79% · entry $2.58 → $1.78
T+1d
-4.26%
call -4.26% · α -3.87%
$2.47
settled 6mo ago
T+5d
-3.88%
call -3.88% · α -3.93%
$2.48
settled 6mo ago
T+20d
-34.88%
call -34.88% · α -38.05%
$1.68
settled 5mo ago
T+60d
-31.01%
call -31.01% · α -35.79%
$1.78
settled 3mo ago
Price Chart
Loading chart...
Executive Summary
NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer to strengthen its leadership team and advance its clinical pipeline. This appointment follows the company's strong momentum and recent positive clinical data from its lead candidates, givastomig and VIS-101.
Key Facts
- NovaBridge Biosciences appointed Mark Hagler as President and Chief Commercial Officer
- Hagler brings deep commercial experience from Sun Pharmaceuticals, Ipsen, Sanofi, Novartis, and Abraxis BioScience
- The appointment strengthens NovaBridge's leadership as it advances givastomig and VIS-101 to pivotal studies
- Hagler will focus on shaping commercial strategy and strengthening pre-commercial readiness
Financial Impact
No financial impact disclosed
executive leadershipcommercial strategypipeline development
Risk Factors
- New executive appointment may lead to strategic shifts
- Commercial strategy development may take time to materialize
Market Snapshot
Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-168315 |
| Document: mark_hagler_pr_-_04-22-2.htm | 0001193125-26-168315 |
| Document: 0001193125-26-168315-index-headers.html | 0001193125-26-168315 |
| Document: 0001193125-26-168315-index.html | 0001193125-26-168315 |
| Document: 0001193125-26-168315.txt | 0001193125-26-168315 |
20 reports for NBP
88% Hit rate @ T+5 Went positive at some point 9 of 10 best @ T+20▲ +19.21%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 25, 2026 2d ago | Press Release | $1.22 | awaiting T+5 | — | $1.25 (+3.29%) |
Oct 23, 2026 4d ago | 6-K | $1.37 | awaiting T+5 | — | $1.25 (−8.39%) |
Oct 13, 2026 14d ago | 6-K | $1.29 $1.43 | ▲ +10.47% | ▲ +11.62% | $1.25 (−2.71%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Sep 8, 2026 7w ago | 6-K | $1.78 $1.61 | ▼ −9.55% | ▼ −8.89% | $1.25 (−29.49%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Aug 20, 2026 9w ago | 6-K | $1.91 $1.89 | ▼ −1.05% | ▼ −2.16% | $1.25 (−34.29%) |
Aug 20, 2026 9w ago | Press Release | $1.91 $1.89 | ▲ +1.05% | ▲ +2.16% | $1.25 (+34.29%) |
Jul 24, 2026 13w ago | 6-K | $1.78 $1.60 | ▼ −10.11% | ▼ −11.19% | $1.25 (−29.49%) |
Showing 10 of 20
US Market Status
Market Closed — Opens Wed (15h 31m)
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers